Latest From MolMed SPA
Fresh Or Frozen? Orchard Aims For Cryopreserved Gene Therapy Approvals Using Pivotal Trials With Fresh Cell Formulations
Orchard aims to submit three ex vivo autologous gene therapies for approval by the end of 2021, helped by a new regenerative medicine advanced therapy designation (for a rare primary immunodeficiency syndrome) and a breakthrough therapy designation (for another rare primary immunodeficiency).
The funding comes as the Dutch biotech closes in on a potential conditional approval and closure of its acquisition of CytoSen.
All-stock transaction combines privately held Oncternal with GTx, which had been considering its strategic alternatives. Biogen acquires gene therapy biotech Nightstar, MaxCyte and Kite expand their CAR-T partnership.
- Gene Therapy, Cell Therapy
- Large Molecule
- Drug Delivery
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- MolMed SPA
- Senior Management
Claudio Bordignon, MD, Pres. & CEO
Enrico Cappelli, CFO
Gian Paolo, MD, Dir., Research
Holger Neecke, PhD, Mgr., Bus. Dev.
- Contact Info
Phone: (39) 2 21277 1
Via Olgettina 58
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.